Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Opus Genetics, Inc.

Get SEC filing alerts via email and in your feed for Opus Genetics, Inc.

IRD

Opus Genetics, Inc.

About Opus Genetics, Inc.

Opus Genetics, Inc. is a biotech company developing gene therapies for inherited retinal diseases (IRDs) and ophthalmic disorders. Its pipeline includes AAV-based gene treatments targeting conditions like Leber congenital amaurosis, retinitis pigmentosa, and Best disease. The company also commercializes the FDA-approved RYZUMVI eye drop for presbyopia and low-light vision issues, focusing on innovative, one-time treatments for vision loss and eye health.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Opus Genetics, Inc.

1
1
Opus Genetics, Inc. Opus Genetics Reports $65.5 Million Net Loss in Q1 2026 Amid Decreased Revenue

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Opus Genetics, Inc. Opus Genetics Reports $49.6 Million Net Loss and $14.2 Million Revenue for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Opus Genetics, Inc. Opus Genetics Reports $17.5 Million Net Loss in Q3 2025, Focuses on Gene Therapy Programs

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Opus Genetics, Inc. Opus Genetics Reports $7.4 Million Net Loss in Q2 2025, Revenue from Collaborations Increases

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Opus Genetics, Inc. Opus Genetics Reports $8.2 Million Net Loss and $4.4 Million Revenue in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Opus Genetics, Inc. Opus Genetics Reports $57.5 Million Net Loss for Fiscal Year 2024 Amid Rising Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Opus Genetics, Inc. Opus Genetics Reports Significant Revenue Decline and Net Loss in Latest Quarter, Completes Acquisition of Opus Genetics, Inc.

Via official filing (AI summary) | over 1 year ago | 0 comments